182 related articles for article (PubMed ID: 3443146)
1. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
2. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
3. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
[TBL] [Abstract][Full Text] [Related]
4. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
[TBL] [Abstract][Full Text] [Related]
5. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
Veronese ME; McLean S
Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
[TBL] [Abstract][Full Text] [Related]
7. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
8. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Al-Dabbagh SG; Idle JR; Smith RL
J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
[TBL] [Abstract][Full Text] [Related]
9. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
[TBL] [Abstract][Full Text] [Related]
10. The metabolism of glyburide in subjects of known debrisoquin phenotype.
Peart GF; Boutagy J; Shenfield GM
Clin Pharmacol Ther; 1989 Mar; 45(3):277-84. PubMed ID: 2493353
[TBL] [Abstract][Full Text] [Related]
11. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
Lledó P; Abrams SM; Johnston A; Patel M; Pearson RM; Turner P
Eur J Clin Pharmacol; 1993; 44(1):63-7. PubMed ID: 8436157
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
[TBL] [Abstract][Full Text] [Related]
14. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Pierce DM; Smith SE; Franklin RA
Eur J Clin Pharmacol; 1987; 33(1):59-65. PubMed ID: 3691597
[TBL] [Abstract][Full Text] [Related]
16. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
[TBL] [Abstract][Full Text] [Related]
17. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
18. Oxidative polymorphism of debrisoquine in Parkinson's disease.
Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
[TBL] [Abstract][Full Text] [Related]
19. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
